<DOC>
	<DOCNO>NCT01137006</DOCNO>
	<brief_summary>A dose escalation study design determine safety , maximum tolerate dose , anti-melanoma activity , antibody blood level progression-free survival patient malignant melanoma receive IMC-20D7S either every two week every three week .</brief_summary>
	<brief_title>An Open-Label , Dose-Escalation Study IMC-20D7S In Patients With Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patient histologically cytologically confirm cutaneous , mucosal , uveal malignant melanoma progress least 1 treatment standard cytotoxic treatment or/and immunotherapy ( eg , treatment cytokine , monoclonal antibody , vaccine ) regard candidate potentially curative , high priority treatment melanoma Patient ≥ 18 year age Patient either measurable disease define RECIST 1.1 evaluable disease At least 21 day must elapse major surgery , prior chemotherapy , prior treatment investigational agent device , prior radiation therapy . Relative patient 's treatment nonapproved biological product ( eg , monoclonal antibody ) , minimum 2 halflives must pass eligibility consider Patient resolution clinically significant toxic effect prior cancer therapy Grade ≤ 1 accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) Version 4.02 Patient adequate hematological function , hepatic function , renal function Patient undergone major surgery ( eg , laparotomy , thoracotomy , removal organ [ ] ) within 21 day prior study entry Patient elective plan surgery conduct trial Patient document and/or symptomatic brain leptomeningeal metastasis Patient receive systemic steroid immunosuppressive medication . ( Intermittent use steroidcontaining medication , eg , asthma exacerbation skin lesion , permit ) Patient uncontrolled undercurrent illness Patient concurrent active malignancy adequately treat nonmelanomatous skin cancer noninvasive carcinoma situ neoplasm Patient know allergy treatment component ( monoclonal antibody therapeutic protein fresh frozen plasma , human serum albumin , cytokine , interleukin ) . In event suspicion patient may allergies , patient exclude Patient pregnant lactating Patient know HIV AIDS infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Phase I</keyword>
	<keyword>antibody</keyword>
	<keyword>melanin</keyword>
	<keyword>tyrosinase relate protein 1</keyword>
	<keyword>glycoprotein</keyword>
	<keyword>20D7S</keyword>
</DOC>